Denifanstat is under clinical development by Sagimet Biosciences and currently in Phase II for Astrocytoma. According to GlobalData, Phase II drugs for Astrocytoma have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Denifanstat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Denifanstat (TVB-2640) is under development for the treatment of metabolic syndrome, astrocytoma, non-alcoholic steatohepatitis, non alcoholic fatty liver disease, liver cirrhosis, advanced solid tumors including breast cancer, non-small cell lung cancer, non-small cell lung carcinoma, colon cancer, metastatic castration resistant prostate cancer and glioblastoma multiforme. It is administered through oral route in the form of tablet. The drug candidate is a small molecule and acts by targeting fatty acid synthase. The drug candidate was also under development for the treatment of chronic hepatitis C, ovarian cancer, peritoneal cancer and acne vulgaris.
Sagimet Biosciences overview
Sagimet Biosciences is a clinical-stage pharmaceutical company that develops novel therapeutics in metabolic diseases. The company offers TVB-2640, a fatty acid synthase inhibitor used for the treatment of solid tumors, including non-small cell lung cancer (NSCLC), breast cancer and ovarian cancer. Its pipeline program includes fatty acid synthase inhibitors and a research platform in the treatment of solid tumors. Sagimet Biosciences provides an FASN inhibitor, an essential enzyme that is responsible for the synthesis of palmitic acid and used in tumor metabolism, tumor cell survival and lipid signaling. The company develops antiviral therapeutic candidates for respiratory syncytial virus, cytomegalovirus, and other human pathogens. Sagimet Biosciences is headquartered in San Mateo, California, the US.
For a complete picture of Denifanstat’s drug-specific PTSR and LoA scores, buy the report here.